Skip to main content

Table 2 Multivariate adjusted risk estimation of different systolic and diastolic blood pressure as well as pulse pressure quartiles for Cardiovascular disease in the total population and those with and without anti-hypertensive medication: Tehran Lipid and Glucose study (1999–2014)

From: Blood pressure components and incident cardiovascular disease and mortality events among Iranian adults with chronic kidney disease during over a decade long follow-up: a prospective cohort study

  BP category Model 1 Model 2
  E/N HR (95% CI) p HR (95% CI) P
Total (N = 1232) SBP < 120 61/367 0.92 (0.63–1.34) 0.67 0.94 (0.64–1.38) 0.75
120 ≤ SBP < 130* 49/224 Ref    Ref   
130 ≤ SBP < 140 42/211 0.95 (0.63–1.44) 0.81 0.87 (0.57–1.32) 0.52
SBP ≥ 140 165/430 1.67 (1.21–2.3) 0.002 1.68 (1.2–2.34) 0.002
Treated (N = 286) SBP < 120 10/36 1.32 (0.5–3.5) 0.57 1.39 (0.51–3.8) 0.52
120 ≤ SBP < 130* 7/27 Ref    Ref   
130 ≤ SBP < 140 12/48 1.19 (0.46–3.04) 0.71 1.09 (0.42–2.87) 0.85
SBP ≥ 140 66/175 1.69 (0.77–3.69) 0.19 2.01 (0.89–4.57) 0.1
Untreated (N = 946) SBP < 120 51/331 0.87 (0.58–1.31) 0.51 0.9 (0.59–1.36) 0.61
120 ≤ SBP < 130* 42/197 Ref    Ref   
130 ≤ SBP < 140 30/163 0.85 (0.53–1.36) 0.5 0.8 (0.5–1.29) 0.37
SBP ≥ 140 99/255 1.62 (1.12–2.34) 0.01 1.64 (1.13–2.39) 0.009
Total (N = 1232) DBP < 80 132/544 1.61 (1.13–2.32) 0.009 1.55 (1.08–2.24) 0.02
80 ≤ DBP < 85* 38/242 Ref    Ref   
85 ≤ DBP < 90 45/165 1.88 (1.22–2.90) 0.004 1.93 (1.25–2.98) 0.003
DBP ≥ 90 102/281 2.68 (1.85–3.89) <0.001 2.63 (1.8–3.83) <0.001
Treated (N = 286) DBP < 80 24/77 2.13 (0.95–4.78) 0.065 2.00 (0.89–4.54) 0.09
80 ≤ DBP < 85* 8/55 Ref    Ref   
85 ≤ DBP < 90 11/38 2.1 (0.84–5.22) 0.11 1.96 (0.77–4.95) 0.16
DBP ≥ 90 52/116 4.02 (1.9–4.85) < 0.001 4.54 (2.13–9.67) <0.001
Untreated (N = 946) DBP < 80 108/467 1.5 (1.0–2.25) 0.049 1.43 (0.95–2.16) 0.09
80 ≤ DBP < 85* 30/187 Ref    Ref   
85 ≤ DBP < 90 34/127 1.84 (1.13–3.01) 0.015 1.94 (1.19–3.18) 0.008
DBP ≥ 90 50/165 2.09 (1.33–3.29) 0.001 1.95 (1.23–3.08) 0.004
Total (N = 1232) PP < 40* 46/327 Ref    Ref   
40 ≤ PP < 50 70/291 1.5 (1.03–2.19) 0.034 1.44 (0.98–2.1) 0.06
50 ≤ PP < 64 79/307 1.43 (0.98–2.08) 0.06 1.28 (0.88–1.87) 0.2
PP ≥ 64 122/307 2.13 (1.48–3.06) <0.001 1.92 (1.33–2.78) 0.001
Treated (N = 286) PP < 40* 12/37 Ref    Ref   
40 ≤ PP < 50 12/42 0.93 (0.42–2.09) 0.87 1.08 (0.47–2.50) 0.86
50 ≤ PP < 64 26/83 0.95 (0.47–1.93) 0.9 1.04 (0.51–2.13) 0.91
PP ≥ 64 45/124 1.06 (0.55–2.06) 0.86 1.16 (0.59–2.27) 0.66
Untreated (N = 946) PP < 40* 34/290 Ref    Ref   
40 ≤ PP < 50 58/249 1.67 (1.09–2.57) 0.019 1.52 (0.98–2.36) 0.058
50 ≤ PP < 64 53/224 1.5 (0.96–2.34) 0.075 1.31 (0.84–2.06) 0.24
PP ≥ 64 77/183 2.54 (1.65–3.91) <0.001 2.34 (1.51–3.63) < 0.001
  1. Age was adjusted by considering it as the time-scale
  2. Model 1: Adjusted for sex
  3. Model 2: Adjusted for sex, BMI, diabetes, hypercholesterolemia, eGFR, smoking and anti-hypertensive medication (only for total population)
  4. BP blood pressure, SBP systolic blood pressure, DBP diastolic blood pressure, pp pulse pressure, E/N events/N, HR hazard ratio, CI confidence interval
  5. *Reference intervals